NCT04679389View on ClinicalTrials.gov

Acetazolamide Efficacy in Ataxia in PMM2-CDG

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 17, 2021

Primary Completion Date

January 24, 2024

Study Completion Date

January 24, 2024

Conditions
Pmm2-CDGCDG1A
Interventions
DRUG

Placebo

administered orally or enterally

DRUG

Acetazolamide

administered orally or enterally

Trial Locations (3)

19104

Children's Hospital of Philadelphia, Philadelphia

55905

Mayo Clinic, Rochester

98105

Seattle Children's Hospital, Seattle

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

Seattle Children's Hospital

OTHER

collaborator

Children's Hospital of Philadelphia

OTHER

lead

Mayo Clinic

OTHER

NCT04679389 - Acetazolamide Efficacy in Ataxia in PMM2-CDG | Biotech Hunter | Biotech Hunter